期刊文献+

密固达抗骨质疏松治疗对患者生活质量的影响分析 被引量:2

Effects of zoledronic acid on quality of life in patients with osteoporosis
在线阅读 下载PDF
导出
摘要 目的:观察并分析密固达抗骨质疏松治疗对改善患者生活质量的临床效果。方法:选取本院2009年6月至2011年6月236例骨质疏松的患者,给予密固达治疗,并应用骨质疏松症评估问卷(OPAQ2)和简明健康生活量表(SF-36)对患者治疗前后进行生活质量的评估。结果:经密固达治疗后,患者的OPAQ和SF-36得分有显著升高,P<0.05。结论:经密固达抗抗骨质疏松治疗后,患者的生活质量得到明显改善,具有临床应用价值。 Objective: To assess the efficacy of zoledronic acid on the quality of life in patients with osteoporosis. Methods: We recruited 236 patients with osteoporosis who were treated with zoledrnnic acid between June 2009 and .June 2011. The questionnaire ( OPAQ2 ) and concise heahh life scale (SF-36) were assessed prior to and after the treatment. Results: Treatment with zoleronic acid yielded a substantial improvement in OPAQ and SF-36 scores in patients with osteoporosis (both P 〈0.05). Conclusion: Treatment with zoledronic acid is associated with considerably improved quality of life patients with osteoporosis and is of clinical significance for application.
出处 《广州医学院学报》 2013年第2期47-49,共3页 Academic Journal of Guangzhou Medical College
基金 广东省科技计划项目(2009B030801051)
关键词 骨质疏松 生活质量 OPAQ2 SF-36 osteoporosis quality of life OPAQ2 SF-36
作者简介 (1970-),女,主任医师,本科
  • 相关文献

参考文献5

二级参考文献23

  • 1彭六保,崔巍.唑来膦酸的临床应用研究进展[J].中国新药与临床杂志,2007,26(3):237-240. 被引量:36
  • 2Cramer JA,Amonkar MM,Hebbom A,et al.Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis[J].Curt Med Res Opin,2005,21(12):1453-1460.
  • 3Lo JC,Pressman AR,Omar MA,et al.Persistence with weekly alendronate therapy among postmenopausal women[J].Osteoperos Int,2006,17(6):922-928.
  • 4Huybrechts KF,lshak KJ,Caro JJ.Assessment of compliance with osteoperosis treatment and its consequences in a managed care population[J].Bone,2006(6),38:922-928.
  • 5Siris ES,Harris ST,Rosen CJ,et al.Adherence to bisphosphonate therapy and fracture rates in osteoporotic women:relationship to vertebral and nonvertebral fractures from 2 US claims databases[J].Mayo Clin Proc,2006.81(8):1013-1022.
  • 6Siris ES,Silverman S,Abbott T,et al.Adherence to bisphosphonates (BPs) is associated with reduced fr acture risk in women with posunenopausal osteoperosis (PMO)[J].Menopanse,2005,12:75.
  • 7Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopansal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
  • 8Lyles KW,Coion-Emetic CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture[J].N Engl J Med,2007,357(18):1799-1809.
  • 9中华医学会编.临床诊疗指南《骨质疏松症和骨矿盐疾病分册》[M].北京:人民卫生出版社,2006:2-3.
  • 10Nguyen ND,Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res, 2006,21 ( 2 ) : 340 -349.

共引文献104

同被引文献7

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部